[Ectopic hormone-producing tumors--research and clinics].
Recent progress in endocrinology, cytokine research, and oncology has provided new information for further understanding of ectopic hormone-producing tumors. The mechanisms responsible for this morbidity need further investigations to clarify the neuroendocrine nature of tumor cells. Meanwhile, a common hormonal substance produced by a specific tumor could serve as a specific tumor marker for the tumor, as is the case of ProGRP for small cell lung cancer. The development of drugs for ectopic hormonal syndrome might be a good lesson of the molecular targeting for hormone signaling pathways. It is reasonable to postulate that the clinical entities covered by the term 'ectopic humoral syndrome' will be increasing.
Yamaguchi
Ken
K
Shizuoka Cancer Center.
D014408:Biomarkers, Tumor / Q000032:analysis; D003937:Diagnosis, Differential; D016503:Drug Delivery Systems; D015195:Drug Design; D006729:Hormones, Ectopic / Q000032:analysis / Q000096:biosynthesis*; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D009384:Paraneoplastic Endocrine Syndromes / Q000175:diagnosis / Q000209:etiology; D010446:Peptide Fragments / Q000032:analysis; D010455:Peptides / Q000032:analysis; D011994:Recombinant Proteins / Q000032:analysis
D014408:Biomarkers, Tumor; D006729:Hormones, Ectopic; D010446:Peptide Fragments; D010455:Peptides; D011994:Recombinant Proteins; C087079:pro-gastrin-releasing peptide (31-98)